5 Oversold Stocks to Buy with Double-Digit ROE Growth

In this article, we will list the 5 Oversold Stocks to Buy With Double-Digit ROE Growth. Please visit 7 Oversold Stocks to Buy With Double-Digit ROE Growth if you’d like to see an extended list and the methodology behind it.

5. Insulet Corp. (NASDAQ:PODD)

Insulet Corp. (NASDAQ:PODD) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On April 6, Evercore ISI reduced the price target on Insulet Corp. (NASDAQ:PODD) from $340 to $240, while maintaining an Outperform rating on the stock. Despite the downward revision to the target price, the stock still offers an adjusted upside of over 21% at the prevailing level.

Image by MayoFi from Pixabay

The adjustment is part of the firm’s broader revisions across medical technologies and life science tools segments, in line with the first-quarter earnings preview.

Back on March 13, Insulet Corp. (NASDAQ:PODD) announced a voluntary medical device correction for specific Omnipod 5 batches distributed within the United States. This crucial safety measure comes on the back of a manufacturing flaw that involved ripped internal insulin delivery tubing. This structural damage causes the drug to leak internally rather than enter the body properly. It significantly increases the risk of fatal diabetic ketoacidosis and extremely high blood glucose levels.

The company confirmed 18 serious adverse events resulting in hospitalization, none of which were fatal. Additionally, the company has explained that this particular anomaly, which affects about 1.5% of yearly global production, has no effect whatsoever on continuous glucose monitoring devices. To ensure that new patients start and uninterrupted customer shipments continue to be fully supported at the current level, management successfully adjusted quality control processes to prevent repeat incidents.

Insulet Corp. (NASDAQ:PODD) focuses on manufacturing and selling insulin management systems through the Omnipod platform. It offers a disposable tubeless pump called Omnipod Insulin Management System, whose design is specific to insulin-dependent diabetes. The company’s strategy revolves around high-volume automated manufacturing in the US and Malaysia, and contract manufacturing in China.